New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
In treating obesity as a chronic disease, the essential goal of weight loss therapy is not the quantity of weight loss as an end unto itself but rather the prevention and treatment of complications to enhance health and mitigate morbidity and mortality. This perspective on obesity care is consistent with the complications-centric American Association of Clinical Endocrinology (AACE) obesity guidelines and the diagnostic term of adiposity-based chronic disease (ABCD). Many complications require 10% to 20% weight loss to achieve therapeutic goals; however, existing obesity medications fail to produce ≥10% weight loss in the majority of patients. In June, 2021, semaglutide 2.4 mg/week was approved for chronic weight management. Phase 3 clinical trials demonstrated that this medication produced > 10% placebo-subtracted weight loss, more than half of patents lost ≥15%, and over one third lost ≥20% of baseline weight. This essentially doubles effectiveness over existing obesity medications, provides sufficient weight loss to ameliorate a broad range of complications, and qualifies as the first member of a second-generation class of obesity medications. The advent of second-generation medications fully enables a treat-to-target approach for management of ABCD as a chronic disease. Specifically, with this degree of efficacy, second-generation medications permit active management of body weight as a biomarker to targets associated with effective treatment and prevention of specific complications. ABCD can now be managed similar to other chronic diseases such as type 2 diabetes, hypertension, and atherosclerosis, which are treated to biomarker targets that can be modified based on the clinical status of individual patients [ie, hemoglobin A1c (HbA1c), blood pressure, and low-density lipoprotein cholesterol (LDL-c)] to prevent the respective complications of these diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, within the GLP-1 RA class, drugs are evolving, and the newer ones (second-generation) are more potent than the initially approved liraglutide for weight management (Garvey, 2022).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Garvey, 2022
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence has consistently demonstrated their benefits in individuals with obesity, including substantial WL (often exceeding the 10% WL achieved with intensive lifestyle interventions), improved quality of life (QoL), and reductions in obesity-related organ damage [7,8].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New generation incretin-based medications such as tirzepatide and semaglutide have been shown to be highly effective in weight reduction in people with obesity or overweight.7”
From Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Despite that 5–10% WL is clinically beneficial, greater WL may be required for the individual to improve or achieve remission of some obesity-related complications [7, 8].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [7]
In the citing paper
“Incretin-based medications have transformed obesity management by enabling substantial body weight reduction.”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [8]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572 · cited 2×
“This raises the question as to whether semaglutide will also reduce CVD events and mortality as has been observed following bariatric surgery (18-20).”
BackgroundFuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012 · cited 1×
“It has since become clear that the excess in adipose tissue mass is the result of abnormalities in satiety hormones interacting with CNS feeding centers (2-4).”
BackgroundXENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 10×
“As a chronic disease, treatment improves the health of patients by preventing and treating obesity complications (5,6).”
BackgroundInfluentialSelf-citation2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report
Evert, A. B., Dennison, M., Gardner, C. D., Garvey, W. T., Lau, K. H. K., MacLeod, J., Mitri, J., Pereira, R. F., Rawlings, K., Robinson, S., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0014 · Cited by 1,496 · cited 1×
“In patients with ABCD and prediabetes or metabolic syndrome, 10% weight loss is maximally effective for preventing progression to overt diabetes (5,12); in patients with T2D, the more weight loss the better where weight loss of >5% to 15% or more provides progressive improvements in HbA1c, blood pressure, and lipids (…”
BackgroundSelf-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Self-citationRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30162-0 · Cited by 738
Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716
Self-citationAllison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Self-citationA proposed clinical staging system for obesity
Sharma, A. M., & Kushner, R. F. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.2 · Cited by 687 · cited 1×
“Several approaches have been proposed for the general staging of patients with obesity such as the Edmonton protocol (46) and the AACE obesity guidelines (5), and cardiometabolic disease staging (47,48) helps clinicians stratify patients over a broad range of risk for progression to T2D and CVD.”
BackgroundGarber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598 · cited 1×
“5% (41) because evidence indicates this will minimize vascular complications such as retinopathy, neuropathy, chronic kidney disease, and CVD risk.”
BackgroundSelf-citationWadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis
Mummadi, R. R., Kasturi, K. S., Chennareddygari, S., & Sood, G. K. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.012 · Cited by 511
Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist
Kühnen, P., Clément, K., Wiegand, S., Blankenstein, O., Gottesdiener, K., Martini, L. L., Mai, K., Blume-Peytavi, U., Grüters, A., & Krude, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512693 · Cited by 485
Association Between Bariatric Surgery and Long-term Survival
Arterburn, D. E., Olsen, M. K., Smith, V. A., Livingston, E. H., Van Scoyoc, L., Yancy, W. S., Eid, G., Weidenbacher, H., & Maciejewski, M. L. (2015) · JAMA · doi:10.1001/jama.2014.16968 · Cited by 479
Lazo, M., Solga, S. F., Horska, A., Bonekamp, S., Diehl, A. M., Brancati, F. L., Wagenknecht, L. E., Pi-Sunyer, F. X., Kahn, S. E., Clark, J. M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0856 · Cited by 367
Heymsfield, S. B., Coleman, L. A., Miller, R., Rooks, D. S., Laurent, D., Petricoul, O., Praestgaard, J., Swan, T., Wade, T., Perry, R. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33457 · Cited by 338 · cited 1×
“muscle mass (56), and the combinations of GLP-1 receptor agonists with other satiety hormones such as amylin (55), PYY, and oxyntomodulin.”
BackgroundMechanick, J. I., Hurley, D. L., & Garvey, W. T. (2017) · Endocrine Practice · doi:10.4158/ep161688.ps · Cited by 320 · cited 5×
“Accordingly, the complications-centric AACE clinical guidelines for obesity emphasize the prevention and treatment of complications as the end point of therapy rather than the amount of weight lost per se (5).”
MethodInfluentialSelf-citationEnebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316 · cited 2×
“muscle mass (56), and the combinations of GLP-1 receptor agonists with other satiety hormones such as amylin (55), PYY, and oxyntomodulin.”
BackgroundPerceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study
Kaplan, L. M., Golden, A., Jinnett, K., Kolotkin, R. L., Kyle, T. K., Look, M., Nadglowski, J., O'Neil, P. M., Parry, T., Tomaszewski, K. J., et al. (2018) · Obesity · doi:10.1002/oby.22054 · Cited by 312
Frühbeck, G., Busetto, L., Dicker, D., Yumuk, V., Goossens, G. H., Hebebrand, J., Halford, J. G. C., Farpour-Lambert, N. J., Blaak, E. E., Woodward, E., et al. (2019) · Obesity Facts · doi:10.1159/000497124 · Cited by 311
The defence of body weight: a physiological basis for weight regain after weight loss
Sumithran, P., & Proietto, J. (2013) · Clinical Science · doi:10.1042/cs20120223 · Cited by 310
MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency
Clément, K., Biebermann, H., Farooqi, I. S., Van der Ploeg, L., Wolters, B., Poitou, C., Puder, L., Fiedorek, F., Gottesdiener, K., Kleinau, G., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0015-9 · Cited by 309
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
Collet, T.-H., Dubern, B., Mokrosinski, J., Connors, H., Keogh, J. M., Mendes de Oliveira, E., Henning, E., Poitou-Bernert, C., Oppert, J.-M., Tounian, P., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.015 · Cited by 302
Aronne, L. J., Wadden, T. A., Peterson, C., Winslow, D., Odeh, S., & Gadde, K. M. (2013) · Obesity · doi:10.1002/oby.20584 · Cited by 274 · cited 1×
“Drug combinations that target multiple pathways produce greater weight loss than when these drugs are used as single agents (57,58).”
BackgroundKwok, C. S., Pradhan, A., Khan, M. A., Anderson, S. G., Keavney, B. D., Myint, P. K., Mamas, M. A., & Loke, Y. K. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.02.026 · Cited by 264
Ryan, D. H., Lingvay, I., Colhoun, H. M., Deanfield, J., Emerson, S. S., Kahn, S. E., Kushner, R. F., Marso, S., Plutzky, J., Brown-Frandsen, K., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.07.008 · Cited by 249 · cited 1×
“The ongoing SELECT trial is a cardiovascular outcome trial powered for superiority in patients with obesity but without diabetes and will hopefully address this question in ABCD (45).”
BackgroundCefalu, W. T., Bray, G. A., Home, P. D., Garvey, W. T., Klein, S., Pi-Sunyer, F. X., Hu, F. B., Raz, I., Van Gaal, L., Wolfe, B. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1081 · Cited by 243
Self-citationCardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.044 · Cited by 243
Self-citationGarvey, W. T., Garber, A. J., Mechanick, J. I., Bray, G. A., Dagogo-Jack, S., Einhorn, D., Grunberger, G., Handelsman, Y., Hennekens, C. H., Hurley, D. L., et al. (2014) · Endocrine Practice · doi:10.4158/ep14280.ps · Cited by 238
Self-citationKuna, S. T., Reboussin, D. M., Borradaile, K. E., Sanders, M. H., Millman, R. P., Zammit, G., Newman, A. B., Wadden, T. A., Jakicic, J. M., Wing, R. R., et al. (2013) · Sleep · doi:10.5665/sleep.2618 · Cited by 231
Guo, F., Moellering, D. R., & Garvey, W. T. (2014) · Obesity · doi:10.1002/oby.20585 · Cited by 202 · cited 1×
“Several approaches have been proposed for the general staging of patients with obesity such as the Edmonton protocol (46) and the AACE obesity guidelines (5), and cardiometabolic disease staging (47,48) helps clinicians stratify patients over a broad range of risk for progression to T2D and CVD.”
BackgroundSelf-citationWinslow, D. H., Bowden, C. H., DiDonato, K. P., & McCullough, P. A. (2012) · Sleep · doi:10.5665/sleep.2204 · Cited by 163
Mechanick, J. I., Garber, A. J., Handelsman, Y., Garvey, W. T., Beir, D. M., Bohannon, N. J. V., Bray, G. A., Bush, M. A., Evans, J. G., Hurley, D. L., et al. (2012) · Endocrine Practice · doi:10.4158/ep12160.ps · Cited by 160
Self-citationHebebrand, J., Holm, J.-C., Woodward, E., Baker, J. L., Blaak, E., Durrer Schutz, D., Farpour-Lambert, N. J., Frühbeck, G., Halford, J. G. C., Lissner, L., et al. (2017) · Obesity Facts · doi:10.1159/000479208 · Cited by 106
Garvey, W. T., & Mechanick, J. I. (2020) · Obesity · doi:10.1002/oby.22727 · Cited by 101
Self-citationGarvey, W. T. (2013) · Endocrine Practice · doi:10.4158/ep13263.ra · Cited by 84
Self-citationWilkinson, L., Yi, N., Mehta, T., Judd, S., & Garvey, W. T. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003232 · Cited by 47 · cited 1×
“Several approaches have been proposed for the general staging of patients with obesity such as the Edmonton protocol (46) and the AACE obesity guidelines (5), and cardiometabolic disease staging (47,48) helps clinicians stratify patients over a broad range of risk for progression to T2D and CVD.”
BackgroundSelf-citationSmith, S. R., Garvey, W. T., Greenway, F. L., Zhou, S., Fain, R., Pilson, R., Fujioka, K., & Aronne, L. J. (2017) · Obesity · doi:10.1002/oby.21811 · Cited by 42
Self-citation
Cited by
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
Self-citationTirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416394 · Cited by 634
Strengths and Limitations of BMI in the Diagnosis of Obesity: What is the Path Forward?
Sweatt, K., Garvey, W. T., & Martins, C. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00580-1 · Cited by 398
“With the advent of second-generation obesity medications such as semaglutide and tirzepatide [99], which can produce degrees of weight loss overlapping with those observed following bariatric surgery, measures of body composition will become more imperative in the evaluation of patients at baseline…”
BackgroundSelf-citationWhat is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Despite that 5 – 10% WL is clinically bene fi cial, greater WL may be required for the individual to improve or achieve remission of some obesity-related complications [7, 8].”
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
“progression of cardiometabolic disease towards these severe consequences [12].”
BackgroundInfluential
Metadata
- Authors
- Garvey, W. T.
- Affiliations
- University of Alabama at Birmingham (US)
- Corresponding author
- Garvey, W Timothy
- ORCID
- Garvey, W Timothy
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2021-12-05
- Volume
- 107
- Issue
- 4
- Pages
- e1339-e1347
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC8947217
- OpenAlex
- W4200495447
- Semantic Scholar
- 182c1e6a99465e8cf1a9f4ffbb50898f1ef8f337
- Cited by
- 110
- References
- 58
- Citations by year
- 2026: 16 · 2025: 37 · 2024: 31 · 2023: 16 · 2022: 10
- FWCI
- 8.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes Digestive and Kidney Diseases
- University of Alabama
- Birmingham Diabetes Research Center (P30 DK079626)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, anti-obesity drugs, semaglutide, treat-to-target, weight loss, obesity complications, chronic disease management, obesity as chronic disease
- MeSH terms
- Chronic Disease, Diabetes Mellitus, Type 2, Endocrinology, Humans, Obesity, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.